menu
    • menu
    [{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lesinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lesinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lesinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lesinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lesinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lesinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lesinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lesinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lesinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lesinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lesinurad","moa":"Solute carrier family 22 member 12","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lesinurad","moa":"Solute carrier family 22 member 12","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lesinurad","moa":"Solute carrier family 22 member 12","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lesinurad","moa":"Solute carrier family 22 member 12","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lesinurad","moa":"Solute carrier family 22 member 12","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lesinurad","moa":"Solute carrier family 22 member 12","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lesinurad","moa":"Solute carrier family 22 member 12","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ardea Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lesinurad","moa":"Solute carrier family 22 member 12","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ardea Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ardea Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ardea Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lesinurad","moa":"Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase IV","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ironwood Pharmaceuticals \/ Medpace, Inc","highestDevelopmentStatusID":"11","companyTruncated":"Ironwood Pharmaceuticals \/ Medpace, Inc"}]

    Find Clinical Drug Pipeline Developments & Deals for Lesinurad

    Menu

    Lesinurad

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ardea Biosciences

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ardea Biosciences

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lesinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.

                            Details : Lesinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Gout.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 05, 2017

                            Lead Product(s) : Lesinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ironwood Pharmaceuticals

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ironwood Pharmaceuticals

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lesinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase IV

                            Sponsor : Medpace, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairmen...

                            Details : Lesinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Gout.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 24, 2017

                            Lead Product(s) : Lesinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase IV

                            Sponsor : Medpace, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ardea Biosciences

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ardea Biosciences

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lesinurad

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence

                            Details : Lesinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 02, 2016

                            Lead Product(s) : Lesinurad

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ardea Biosciences

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ardea Biosciences

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lesinurad

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability

                            Details : Lesinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 21, 2015

                            Lead Product(s) : Lesinurad

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ardea Biosciences

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ardea Biosciences

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lesinurad

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lesinurad Tablet Bioequivalence

                            Details : Lesinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 01, 2014

                            Lead Product(s) : Lesinurad

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ardea Biosciences

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ardea Biosciences

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lesinurad

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioavailability of Lesinurad and Intravenous [14C]Lesinurad

                            Details : Lesinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 20, 2014

                            Lead Product(s) : Lesinurad

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ardea Biosciences

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ardea Biosciences

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lesinurad

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Metformin and Furosemide Drug-Drug Interaction Study

                            Details : Lesinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 07, 2014

                            Lead Product(s) : Lesinurad

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ardea Biosciences

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ardea Biosciences

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lesinurad

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lesinurad Tablet Relative Bioavailability

                            Details : Lesinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 18, 2013

                            Lead Product(s) : Lesinurad

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Ardea Biosciences

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ardea Biosciences

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lesinurad

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Antacid Interaction Study

                            Details : Lesinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 13, 2013

                            Lead Product(s) : Lesinurad

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ardea Biosciences

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ardea Biosciences

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lesinurad

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lesinurad Interaction Study With Ranitidine

                            Details : Lesinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 25, 2013

                            Lead Product(s) : Lesinurad

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth